Breast cancer is clinically divided into four molecular subtypes, namely, luminal A and B; HER2-positive, and triple-negative breast cancer (TNBC) by the expression of ER, PR, HER2, and KI-67, but such a classification cannot fully realize personalized precision medicine for treating breast cancer. Here, ESR1 is linked to breast carcinoma.